Risk factors for the development of placebo adverse reactions in a multicenter clinical trial
- 31 July 1994
- journal article
- clinical trial
- Published by Elsevier in Annals of Epidemiology
- Vol. 4 (4) , 327-331
- https://doi.org/10.1016/1047-2797(94)90089-2
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Long-Term Therapy With Low-Dose Isotretinoin for Prevention of Basal Cell Carcinoma: A Multicenter Clinical TrialJNCI Journal of the National Cancer Institute, 1992
- A Method for the Detection and Management of Adverse Events in Clinical TrialsDrug Information Journal, 1991
- Isotretinoin-basal cell carcinoma prevention trialControlled Clinical Trials, 1990
- The consent form as a possible cause of side effectsClinical Pharmacology & Therapeutics, 1987
- Blinding, unblinding, and the placebo effect: An analysis of patients' guesses of treatment assignment in a double-blind clinical trialClinical Pharmacology & Therapeutics, 1987
- Adverse Nondrug ReactionsNew England Journal of Medicine, 1968
- Pre-existing Conditions, Placebo Reactions, and "Side Effects"Annals of Internal Medicine, 1964
- THE FEET OF CLAY OF THE DOUBLE-BLIND TRIALThe Lancet, 1963
- THE POWERFUL PLACEBOJAMA, 1955
- Effects of Placebo Administration and Occurrence of Toxic ReactionsJAMA, 1954